ACHV · Achieve Life Sciences, Inc.
$7.59
+0.34 (+4.69%)
At close · Aug 14
Market Cap
$781.03M
Shares
102.90M
Achieve Life Sciences, Inc. Earnings Call Transcripts
Every quarterly earnings call for Achieve Life Sciences, Inc. (ACHV) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-11
Achieve Life Sciences, Inc. Q2 FY2026 Earnings Call
Diluted EPS
$-0.80
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-07-02
Annual Meeting of Stockholders
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Achieve Life Sciences, Inc. Q1 FY2026 Earnings Call
Confident tone
Competitive Landscape in Smoking Cessation
Unmet Need and Public Health Opportunity
Commercial Launch Preparation
Diluted EPS
$-0.19
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Achieve Life Sciences, Inc. Q4 FY2025 Earnings Call
Confident tone
NDA submission and FDA progress
Payer access and pricing
Cytisinicline commercial launch preparation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Achieve Life Sciences, Inc. Q3 FY2025 Earnings Call
Confident tone
Cytisinicline efficacy and clinical data
Regulatory milestones and PDUFA
Commissioner's National Priority Voucher (CNPV) for vaping
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Achieve Life Sciences, Inc. Q2 FY2025 Earnings Call
Confident tone
Commercial launch planning and Omnicom partnership
Cytisinicline clinical and safety profile
NDA submission and regulatory progress
Diluted EPS
$-0.37
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Achieve Life Sciences, Inc. Q1 FY2025 Earnings Call
Confident tone
NDA Submission Progress
Cytisinicline Clinical Profile
Market Opportunity and Unmet Need
Diluted EPS
$-0.37
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Achieve Life Sciences, Inc. Q4 FY2024 Earnings Call
Confident tone
NDA submission for cytisinicline (smoking cessation)
Market opportunity / unmet need in nicotine dependence
Vaping cessation indication (ORCA-V2)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Achieve Life Sciences, Inc. Q3 FY2024 Earnings Call
Confident tone
Cytisinicline Product Profile and Market Opportunity
NDA Submission and Regulatory Progress
Vaping Phase 3 Trial (ORCA-V2)
Diluted EPS
$-0.36
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Achieve Life Sciences, Inc. Q2 FY2024 Earnings Call
Confident tone
Cytisinicline Regulatory Progress
Vaping Cessation Indication
Clinical Trial Enrollment
Diluted EPS
$-0.25
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Achieve Life Sciences, Inc. Q1 FY2024 Earnings Call
Confident tone
ORCA-OL long-term safety trial initiation and enrollment
NDA submission timeline and FDA agreement
Vaping cessation and label expansion opportunity
Diluted EPS
$-0.26
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Achieve Life Sciences, Inc. Q4 FY2023 Earnings Call
Confident tone
Clinical efficacy of cytisinicline
FDA agreement and NDA path forward
ORCA-OL long-term safety trial
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Achieve Life Sciences, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.34
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Achieve Life Sciences, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.43
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Achieve Life Sciences, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Achieve Life Sciences, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Achieve Life Sciences, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-1.35
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Achieve Life Sciences, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.08
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Achieve Life Sciences, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.80
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Achieve Life Sciences, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Achieve Life Sciences, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-0.71
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Achieve Life Sciences, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-1.53
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Achieve Life Sciences, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Achieve Life Sciences, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Achieve Life Sciences, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Achieve Life Sciences, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Achieve Life Sciences, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Achieve Life Sciences, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
949858
CUSIP
004468500
13F (30d)
111 filings
109 filers
Visit website
Investor relations